Literature DB >> 33706747

Giant congenital nodular melanoma in a newborn: a case report and literature review.

Jun Zhou1, Meng-Xing Lv1, Ling Duan2, Yu-Cheng Xie1, Zhi-Xiang A1, Hong-Fang Wu1, Yan Gao3.   

Abstract

BACKGROUND: Malignant melanoma (MM) arises predominantly after adolescence and is uncommon in children. Congenital MM in newborns is even rarer with a dearth of published literature; as a consequence, there is no uniform standard for the pathogenesis and treatment for neonatal malignant melanoma. Herein we report a case of giant congenital nodular MM in a newborn, including its clinical, imaging, pathological and molecular pathological features. This case is the largest giant congenital primary nodular malignant melanoma in utero in neonates currently reported in China. CASE
PRESENTATION: A female neonatal patient was found to have a 2.97 cm× 1.82 cm×1.50 cm mass with a clear boundary at the right acromion in color Doppler ultrasound examination at 24 weeks of gestation. The mass increased to 3.0 cm×5.0 cm×9.0 cm at birth, and local ulceration was seen. MRI demonstrated that the mass was located on the right shoulder and underarm in a lobulated appearance, and surrounded the right scapula which was deformed. Clinical stage:IV(AJCC 8th Edition (2017)). α-Fetoprofein (AFP) by hematological examination: 1210ng/ml, NSE: 21.28ng/ml, LDH: 842U/L. The patient underwent surgical resection of the tumor, and was pathologically diagnosed as neonatal congenital malignant melanoma; immunohistochemistry (IHC): S-100 (+), HMB45 (+), Melan A (+), and Tyrosinase (+). Molecular pathological examination for BRAF V600E showed no mutations (Quantitative Real-time PCR, qPCR); And so were NRAS, C-kit (exons 9,11,13,14,17,18), and TERT (promoter locus, C228T and C250T) (Sanger sequencing). Non-surgical therapies were not carried out after the surgical resection of the tumor. After 6 months of follow-up, the child developed normally, and color Doppler ultrasound showed no obvious tumor growth or abnormality in the original tumor site.
CONCLUSIONS: It is extremely rare to see giant congenital primary nodular MM in utero in neonates. The pathogenesis, treatment and prognosis of congenital MM need further research. The diagnosis mainly depends on histopathology and immunohistochemistry, and it needs to be differentiated from malignant lymphoma and primitive neuroectodermal tumor. The current treatment strategy for MM relies on the surgical excision of the mass. Research directed at molecular detection for genetic mutations would contribute to targeted therapy and better prognosis.

Entities:  

Keywords:  Case report; Child; Congenital; Melanoma; Pathological presentation; Pediatric; Proliferative nodules

Year:  2021        PMID: 33706747      PMCID: PMC7948322          DOI: 10.1186/s12887-021-02590-7

Source DB:  PubMed          Journal:  BMC Pediatr        ISSN: 1471-2431            Impact factor:   2.125


  24 in total

1.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 2.  Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

Authors:  Stefan Suciu; Alexander M M Eggermont; Paul Lorigan; John M Kirkwood; Svetomir N Markovic; Claus Garbe; David Cameron; Srividya Kotapati; Tai-Tsang Chen; Keith Wheatley; Natalie Ives; Gaetan de Schaetzen; Achmad Efendi; Marc Buyse
Journal:  J Natl Cancer Inst       Date:  2018-01-01       Impact factor: 13.506

3.  Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults--the Stanford experience 1995-2008.

Authors:  David R Berk; Elizabeth LaBuz; Soheil S Dadras; Denise L Johnson; Susan M Swetter
Journal:  Pediatr Dermatol       Date:  2010-04-09       Impact factor: 1.588

Review 4.  Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma.

Authors:  Stephen K Richardson; Zeina S Tannous; Martin C Mihm
Journal:  J Am Acad Dermatol       Date:  2002-07       Impact factor: 11.527

5.  Spitzoid and non-spitzoid melanoma in children: a prognostic comparative study.

Authors:  S Paradela; E Fonseca; S Pita-Fernández; V G Prieto
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-08-29       Impact factor: 6.166

Review 6.  Pathology and genomics of pediatric melanoma: A critical reexamination and new insights.

Authors:  Armita Bahrami; Raymond L Barnhill
Journal:  Pediatr Blood Cancer       Date:  2017-09-12       Impact factor: 3.167

7.  Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009.

Authors:  David A Siegel; Jessica King; Eric Tai; Natasha Buchanan; Umed A Ajani; Jun Li
Journal:  Pediatrics       Date:  2014-09-08       Impact factor: 7.124

8.  Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base.

Authors:  Julie R Lange; Bryan E Palis; David C Chang; Seng-Jaw Soong; Charles M Balch
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

9.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

Review 10.  Melanoma in congenital melanocytic naevi.

Authors:  V A Kinsler; P O'Hare; N Bulstrode; J E Calonje; W K Chong; D Hargrave; T Jacques; D Lomas; N J Sebire; O Slater
Journal:  Br J Dermatol       Date:  2017-04-04       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.